← Back to Clinical Trials
Recruiting NCT04132895

NCT04132895 ICONIC: Improving Outcomes Through Collaboration in OsteosarComa

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04132895
Status Recruiting
Phase
Sponsor University College, London
Condition Osteosarcoma
Study Type OBSERVATIONAL
Enrollment 300 participants
Start Date 2019-10-25
Primary Completion 2025-01-31

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL
Interventions
observational only, no interventions are prescribed in protocol.

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 300 participants in total. It began in 2019-10-25 with a primary completion date of 2025-01-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

There has been little improvement in outcome for patients with osteosarcoma (OS) over the last 20 years. There have been only a few clinical trials of new treatments and no major new therapies introduced recently. This is in part because there is no good understanding of the biology of osteosarcoma, but also trials have only included subgroups of patients. The more that is understood about how and why osteosarcoma arises and grows the better clinicians will be able to decide what treatments are most likely to work best. The purpose of this project is to collect high quality clinical data about patients of all ages with osteosarcoma, such as information about the size of the disease, how it was diagnosed and where it is at diagnosis, what treatments were given and how the disease responded the treatments. Blood and tissue samples will also be collected for analysis in research laboratories. By looking at the results of the laboratory findings and the clinical data together, the questions will start to be answered about why osteosarcomas arise and grow, what makes it spread, and why some patients respond to treatment better than others. As time goes on, this information is planned to be used to develop clinical trials of new treatments. Alongside this, the aim is to find out more about how osteosarcoma and its treatments affect the lives of those living with this disease. This information will help provide the most appropriate care and support that will meet the needs of each patient. Ultimately, the aim is to improve the care and treatment of osteosarcoma patients so that they may live longer and better lives.

Eligibility Criteria

Inclusion Criteria: * New histological diagnosis of osteosarcoma or in the absence of osteoid seen on biopsy, pathology and imaging supportive of a diagnosis of osteosarcoma. (It is well recognised that some patients may present with features suggestive of osteosarcoma (under 40 years, radiological abnormality compatible) but in whom no osteoid is detected in needle biopsy. Although categorised as spindle cell tumour of bone, such patients are usually treated in an identical approach to osteosarcoma. A definite diagnosis of osteosarcoma is then often possible after surgery when the entire resection specimen is available.) * Written informed consent of patient and/or parent/legal guardian. Exclusion Criteria: • Diagnosis more than four months prior to registration.

Contact & Investigator

Central Contact

Krystyna Reczko

✉ ctc.iconic@ucl.ac.uk

📞 020 7679 9878

Principal Investigator

Sandra Strauss, MD

PRINCIPAL INVESTIGATOR

University College Hospitals London

Frequently Asked Questions

Who can join the NCT04132895 clinical trial?

This trial is open to participants of all sexes, studying Osteosarcoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04132895 currently recruiting?

Yes, NCT04132895 is actively recruiting participants. Contact the research team at ctc.iconic@ucl.ac.uk for enrollment information.

Where is the NCT04132895 trial being conducted?

This trial is being conducted at London, United Kingdom, Aberdeen, United Kingdom, Birmingham, United Kingdom, Birmingham, United Kingdom and 11 additional locations.

Who is sponsoring the NCT04132895 clinical trial?

NCT04132895 is sponsored by University College, London. The principal investigator is Sandra Strauss, MD at University College Hospitals London. The trial plans to enroll 300 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology